According to the National Institute of Health, in boys, the leading inherited cause of macular degeneration is X-linked juvenile retinoschisis with an approximate prevalence of 1 in 5,000-25,000. It accounts for approximately 5% of all childhood-onset, inherited retinal dystrophies. There is no specific treatment to stop the disorder but there are several gene therapy trials underway to correct abnormal genes in the retina. These emerging drugs are expected to slow down the progression of disease and prevent vision loss in the coming years.
Major companies involved in the Juvenile Macular Degeneration (JMD) pipeline drugs market include Astellas Institute for Regenerative Medicine and Ascidian Therapeutics, Inc., among others.
Leading drugs currently under pipeline include ACDN-01among others.
Several clinical trials are focused on assessing the efficacy of gene therapies to prevent and treat juvenile macular degeneration (JMD).
The Juvenile Macular Degeneration (JMD) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into juvenile macular degeneration (JMD) drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for juvenile macular degeneration (JMD). The report includes the analysis of over 20+ pipeline drugs and 10+ companies. The juvenile macular degeneration (JMD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Juvenile Macular Degeneration (JMD).
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to juvenile macular degeneration (JMD).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Juvenile macular degeneration refers to several inherited and rare disorders which affect children and young adults. These disorders include Best disease, Stargardt's disease, and juvenile retinoschisis. These disorders cause central vision loss which often starts in childhood or sometimes in young adulthood. Juvenile macular degeneration damages the macula, which is the tissue in the center of the retina at the back of the eye. This is the region which provides sharp central vision and allows us to do things, see colors and recognize faces. These conditions are passed down in families from gene changes. Stargardt’s disease is only inherited if the two parents are affected by the gene. It can be inherited even if one of the parents is affected in the case of Best’s vitelliform macular dystrophy and in the case of juvenile retinoschisis affects males as it is linked to the X chromosome, but it is transmitted from mother to child.
The symptoms of juvenile macular degeneration include the display of gray and black spots, photophobia, blurred vision with dark areas, impairment of color perception, and yellowish flecks around the macula among others. There is no treatment available for juvenile macular degeneration. Visual aids, adaptive training, and some other tools can help people with vision loss remain active. Sunglasses with ultraviolet protection and to perform mobility exercises for patients are recommended. Several studies and research continue to find ways to prevent and manage JMD. Pharma companies and research institutes are developing innovative gene therapies. Alkeus Pharmaceuticals for Regenerative Medicine announced promising results from its TEASE-3 clinical trial for the drug ALK-001. The increasing clinical trials and changing dynamics are impacting the juvenile macular degeneration (JMD) clinical trial landscape significantly.
This section of the report covers the analysis of Juvenile Macular Degeneration (JMD) based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I and II covers a major share of the total clinical trials for juvenile macular degeneration (JMD) as there are not many drugs present in late-stage clinical trials.
The drug molecules categories covered under juvenile macular degeneration (JMD) pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapy. Astellas Institute is conducting a phase I/II trial for Biological: MA09-hRPE. The trial is assessing the subretinal injection of human embryonic stem cell-derived retinal pigment epithelium cells in patients suffering from Stargardt's macular dystrophy. Gene therapies are also being under several trials to prevent and treat JMD. The therapy works by correcting the abnormal gene in the retina. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for juvenile macular degeneration (JMD).
The EMR report for the juvenile macular degeneration (JMD) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in juvenile macular degeneration (JMD) clinical trials:
Leading drugs in the pipeline are as follows:
The trial is designed to assess the tolerability and safety of RPE cellular therapy in patients with Stargardt's macular dystrophy. The trial is sponsored by Astellas Institute for Regenerative Medicine and is currently under phase I/II.
The objective of the study is to assess the safety and efficacy of ACDN-01 following a single subretinal injection of ACDN-01. This is the first human clinical trial in which ACDN-01 will be evaluated, sponsored by Ascidian Therapeutics, Inc. and is currently under phase I/II.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Juvenile Macular Degeneration (JMD) Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for juvenile macular degeneration (JMD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within juvenile macular degeneration (JMD) pipeline insights.
Global Age-Related Macular Degeneration Market
Macular Degeneration Drug Pipeline Analysis
Neovascular Age-Related Macular Degeneration Treatment Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share